Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed stage II or IIIA non-small cell lung cancer
• * T1-3, N1-2, M0
• * No stage IIIB (e.g., contralateral N3), stage IV (M1), or T3, N0, M0 disease
• * N1 disease eligible only if hilar lymph node involvement present
• * No bronchoalveolar carcinoma with lobar or multilobar involvement
• * No small cell lung carcinoma, including mixed histology
• No more than 7 weeks since prior surgery (lobectomy, sleeve resection, bilobectomy, or pneumonectomy)
• * Negative surgical margins
• * No incompletely resected gross disease OR
• * No microscopically positive bronchial or vascular margins
• No known CNS metastasis
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Zubrod 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 2,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Not specified
• Renal:
• Creatinine no greater than 1.5 mg/dL OR
• Creatinine clearance greater than 60 mL/min
• Cardiovascular:
• No superior vena cava syndrome
• Pulmonary:
• FEV\_1 at least 1.0 L
• Gastrointestinal:
• No prior celiac disease, familial polyposis, Turcot's syndrome, Gardner's syndrome, Peutz-Jegher's syndrome, or hereditary non-polyposis colon cancer
• No prior colitis, inflammatory bowel disease, or pancreatitis within the past 10 years
• Other:
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception
• No known sensitivity to rodent proteins
• No prior hypersensitivity or contraindication to study treatments (e.g., monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, aluminum hydroxide, or murine proteins) or any excipients
• No prior clinically significant hypersensitivity reactions (e.g., angioedema, anaphylaxis, or serious dermatological manifestations) or asthmatic attacks requiring hospitalization
• No prior immune or immunodeficiency disorders (e.g., HIV, sarcoidosis, tuberculosis, rheumatoid arthritis, or autoimmune disorders)
• No prior seizure disorder requiring continuous medication
• No active infection
• No other prior or concurrent malignancy within the past 3 years except surgically treated carcinoma in situ of the cervix or squamous cell or basal cell skin cancer
• No medical contraindication to surgery, radiotherapy, or immunotherapy
• No prior drug or alcohol abuse (excluding nicotine) within the past 12 months
• No prior psychiatric or addictive disorder that would preclude study compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior murine antibodies (e.g., OncoScint scan)
• No prior monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, or other investigational carcinoembryonic antigen-derived therapy
• At least 3 years since other prior immunotherapy
• At least 30 days since prior immunization (e.g., influenza)
• No immunomodulatory therapy (e.g., gold, auranofin, hydroxychloroquine, sulfasalazine, penicillamine, levamisole, dapsone, azathioprine, intravenous immunoglobulin, leukotriene antagonists, cromoglycate, ketotifen, nedocromil, psoralin-ultraviolet-light, or plasmapheresis) within 30 prior to the first dose of study drug or 5 half-lives of the action of the agent, whichever is longer
• Chemotherapy:
• At least 3 years since prior chemotherapy except topical therapy
• No concurrent methotrexate or cyclophosphamide
• Endocrine therapy:
• At least 45 days since prior corticosteroids
• No concurrent systemic corticosteroids
• Radiotherapy:
• No prior thoracic radiotherapy
• Surgery:
• See Disease Characteristics
• Other:
• At least 45 days since prior immunosuppressants
• No investigational agents within 30 prior to the first dose of study drug or 5 half-lives of the action of the agent, whichever is longer
• No concurrent amifostine
• No concurrent cyclosporine
• No other concurrent immunosuppressants
• No concurrent chronic systemic antihistamines